Cat. #160916
REME016-2 Uterine corpus cancer organoid
Cat. #: 160916
Sub-type: Organoids
Unit size: 40-100 uL of cell pellet/vial, 1ml
Availability: 8-10 weeks
Organism: Human
Tissue: Uterus
£2,500.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Medical-Industrial Translational Research Center
Institute: Fukushima Medical University
Primary Citation: Tamura et al. 2018. Oncology reports 40: 635-646. PMID: 29917168
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Tool name: REME016-2 Uterine corpus cancer organoid
- Alternate name: REME016-2, REME16-2, REME16, REME016
- Cancer: Carcinoma;Gynaecologic cancer
- Cancers detailed: Clear cell carcinoma;Uterine corpus
- Age y o : 60
- Research fields: Cancer
- Tool sub type: Organoids
- Organism: Human
- Tissue: Uterus
- Gender: Female
- Growth properties: Suspension
- Application: 3D cell culture, High-throughput screening, Xenograft model
- Description: A series of novel patient-derived organoids (PDOs) have been constructed from different tumor tissue types under the Fukushima Translational Research Project, designated as F-PDO. F-PDOs form large cell clusters with a morphology similar to the original tumor and can be cultured for more than six months. Our comparative histological and comprehensive gene expression analyses have shown that the characteristics of F-PDOs were similar to their source tumors, even after long-term growth in culture conditions
- Biosafety level: 2
Handling
- Format: Frozen
- Passage number: 5
- Growth medium: Cancer Cell Expansion Media (Fujifilm Wako Pure Chemical, Ltd.).
- Temperature: 37° C
- Atmosphere: 5% CO2
- Volume: 1 ml
- Storage medium: CELLBANKER 2
- Storage conditions: Liquid Nitrogen
- Shipping conditions: Dry ice
- Characterisation tests: Pathogen and stelility test; Comprehensive gene expression analysis; Cancer panel sequencing; Whole exome sequencing; Anticancer drug susceptibility testing
- Mycoplasma free: Yes
- Biosafety level: 2
Application Details
- Application: 3D cell culture, High-throughput screening, Xenograft model
Related Tools
- Related tools: REME015-3 (same patient)
References
- Tamura et al. 2018. Oncology reports 40: 635-646. PMID: 29917168
